Tharimmune Strengthens Patent Portfolio for TH-104

Tharimmune Inc., a biotechnology company focused on treating inflammation and other critical medical needs, has expanded its intellectual property portfolio for TH-104, a transmucosal film. Newly granted patents in markets such as Japan, Mexico, Australia, and the U.S. secure the long-term potential of TH-104. These patents support the company's strategy to broaden indications, initiating with its use as a medical countermeasure against high-potency opioids for military personnel and first responders.

The company received positive feedback from the FDA for a 505(b)(2) New Drug Application for TH-104, indicating no need for additional trials. Tharimmune aims to develop TH-104 not only as a tool for national security but also for other medical needs like chronic pruritus associated with liver and kidney diseases.